News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Genzyme unloads Dx unit
You may also be interested in...
Earnings Calls In Brief
Johnson & Johnson’s mid-year Synthes purchase drives third-quarter revenue growth. Abbott spin-off on track. More news briefs.
FDA Severe-Bleeding Workshop Addresses Need For Effective Local Agents
Panelists at a recent FDA workshop on severe bleeding said there is a need for effective local agents to treat severe bleeding in trauma and surgical cases, and explored a set of primary clinical endpoints for studying the products in rigorous trials.
FDA Severe-Bleeding Workshop Addresses Need For Effective Local Agents
Panelists at a recent FDA workshop on severe bleeding said there is a need for effective local agents to treat severe bleeding in trauma and surgical cases, and explored a set of primary clinical endpoints for studying the products in rigorous trials.